Abstracts Archive - Page 130 of 2607 - ACR Meeting Abstracts

Abstract Number: 1776 • ACR Convergence 2025
Preclinical Development of a Novel TL1A-Targeting Antibody with Extended Half-life and Low Immunogenicity Risk for the Treatment of Inflammatory Diseases
Yali Zhou¹, Huilin Li¹, Hang Su¹, Mingjun Zhao¹, Haiying Wang¹, Qiong Wang¹, Xiaojin Zhang², Yanliu Fan¹, Lulu Li¹, Miaomiao Wang¹, Jinglu Xia¹, Wenyue Zong¹, Jingjing Li¹, Simin Yi¹, Bing Zou¹, Zhen Lu¹, Yali Wang¹, Yupeng Zhu¹, Lingjian Yang¹, Zenglin Pei¹, Barry Duplantis³, Yuhao Wang³, Yi Li¹ and Quan Yu¹, ¹Ailux, Shanghai, China (People's Republic), ²XtalPi, Shanghai, China (People's Republic), ³Ailux, Boston, MA
Background/Purpose: Autoimmune and inflammatory diseases such as inflammatory bowel disease (IBD) and psoriasis are driven by dysregulated cytokine networks. TL1A, a member of the TNF…
Abstract Number: 1879 • ACR Convergence 2025
Infections in Hospitalized Patients With and Without Psoriatic Arthritis (2016–2021): A National Inpatient Sample Study
Ayema Haque, Ana Salas, Bruna Diniz, Harshank Patel and Philip Kroth, Western Michigan University School of Medicine, Kalamazoo, MI
Background/Purpose: Psoriatic arthritis (PsA) is a chronic, immune-mediated inflammatory disorder affecting up to 30% of psoriasis patients and is associated with increased infection risk. This…
Abstract Number: 1815 • ACR Convergence 2025
New-Onset Juvenile Spondyloarthritis is Characterized by Bone Metabolism Disturbances with Biomarker Potential
Brittney Newby¹, Timothy Brandon¹, Pamela Weiss² and E. John Wherry³, ¹Children's Hospital of Philadelphia, Philadelphia, PA, ²Childrens Hospital of Philadelphia, Philadelphia, PA, ³University of Pennsylvania, Philadelphia, PA
Background/Purpose: Juvenile spondyloarthritis (JSpA) management is hindered by the lack of reliable biomarkers to predict which patients will develop progressive structural changes, such as erosions…
Abstract Number: 1827 • ACR Convergence 2025
Transcriptomics and Machine Learning Unraveling the Molecular Drivers of PFAPA Flares
Sivia Lapidus¹, Tresa Ambooken², Ellen Hakim³, Tara Lozy⁴, Elahe Golalipour³, Sohail Adonimohammed⁵, Jennifer Weiss⁶, Suzanne Li⁶, Amanda Nowakowski⁷, Aryeh Lejtman⁸, Aaron Sebbag³, Ariel Aptekmann⁹ and Jigar Desai⁹, ¹Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Montclair, NJ, ²Food and Drug Administration, Floral Park, NY, ³Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, ⁴Joseph M. Sanzari Children's Hospital, Center for Discovery and Innovation, Hackensack Meridian School of Medicine, Nutley, ⁵Hackensack Meridian School of Medicine, Nutley, NJ, ⁶Joseph M. Sanzari Children's Hospital and Hackensack Meridian School of Medicine, Hackensack, NJ, ⁷Joseph M. Sanzari Children's Hospital, Hackensack Meridian Health, Hackensack, NJ, ⁸Joseph M. Sanzari Children's Hospital and Center for Discovery and Innovation, Hackensack Meridian Health, Nutley, NJ, ⁹Center for Discovery and Innovation and Hackensack Meridian School of Medicine, Hackensack Meridian Health, Nutley, NJ
Background/Purpose: Periodic Fever, Aphthous Stomatitis, Pharyngitis, and Adenitis (PFAPA) is the most common periodic fever presenting with frequent episodes of pain and impaired function. While…
Abstract Number: 1824 • ACR Convergence 2025
Tissue-Resident Natural Killer Cells May Drive Monocyte Differentiation And Macrophage Accumulation In The Inflamed Joints Of Pediatric Juvenile Idiopathic Arthritis Patients
Roselyn Fierkens¹, Jun Inamo², Clara Lin³, Nathan Rogers⁴, Kari Hayes¹, Heather Leach³ and Kentaro Yomogida¹, ¹University of Colorado, Aurora, CO, ²University of Colorado School of Medicine, Aurora, CO, ³Children's Hospital Colorado, Aurora, ⁴Children’s Hospital Colorado, Aurora, CO
Background/Purpose: Natural Killer (NK) cells are the most abundant innate lymphoid cells, accounting for 10–40% of total lymphocytes in peripheral blood. They adapt to diverse…
Abstract Number: 1869 • ACR Convergence 2025
A miRNA signature consisting of high Let7i-5p, high miR-483-5p, low miR-223- 3p characterizes connective tissue diseases with interstitial lung disease
Olga Sanchez Pernaute¹, Mª Jesus Rodriguez-Nieto², Cristina Vadillo Font³, Maria asuncion Nieto³, Laura Cebrian⁴, Belen Lopez Muñiz⁵, Hilda Godoy Tundidor⁶, Rosalia Laporta⁷, Jesus Loarce Martos⁸, Juan A Rigual⁸, fredeswinda Romero-Bueno⁹, Irene Llorente Cubas¹⁰, Claudia Valenzuela¹⁰, Gema Bonilla¹¹, Luis Gomez Carrera¹², Rosario Garcia Vicuña¹³, Ana Jaureguizar⁸, Jose Luis Morell Hita⁸ and lydia Abasolo Alcazar¹⁴, ¹Clinica Universidad de Navarra, Madrid, Madrid, Spain, ²Fundacion Jimenez Diaz (IIS-HUFJD), Madrid, Spain, ³Hospital Clínico S Carlos, Madrid, Spain, ⁴Department of Rheumatology, Hospital Universitario Infanta Leonor / Universidad Complutense de Madrid, Madrid, Spain, Madrid, Spain, ⁵Hospital Universitario Infanta Leonor, Madrid, Spain, ⁶Hospital Universitario puerta de hierro, Madrid, Spain, ⁷Hospital Puerta de Hierro Majadahonda, Madrid, Spain, ⁸Hospital Ramón y Cajal, Madrid, Spain, ⁹University Hospital Fundación Jiménez Díaz"", Madrid, Spain, ¹⁰Hospital Universitario Princesa, Madrid, Spain, ¹¹Hospital Universitario La Paz, Rheumatology, Madrid, Madrid, Spain, ¹²Hospital Universitario La Paz, Madrid, Spain, ¹³Hospital Universitario de la Princesa, Madrid, Spain, ¹⁴IdISSC. HCSC, Madrid, Madrid, Spain
Background/Purpose: Patients with interstitial lung disease associated to a connective tissue disease (CTD-ILD) are a heterogeneous population both concerning mechanisms and trajectories. In an RNA…
Abstract Number: 1769 • ACR Convergence 2025
Classification of Relapses of Eosinophilic Granulomatosis with Polyangiitis After Two-Years of Treatment with Anti-Interleukin-5/Receptor Therapy
Christian Pagnoux¹, Arnaud Bourdin², Bernhard Hellmich³, Nader Khalidi⁴, David Jackson⁵, David Jayne⁶, Parameswaran Nair⁷, Ulrich Specks⁸, Benjamin Terrier⁹, Lena Börjesson Sjö¹⁰, Priya Jain¹¹, Aadarsh Lal¹², Sofia Necander¹³, Claire Walton¹⁴, Michael Wechsler¹⁵ and Peter Merkel¹⁶, ¹Mount Sinai Hospital, University Health Network, Toronto, and Canadian Vasculitis Research Network (CanVasc), Toronto, ON, Canada, ²Department of Respiratory Diseases, Montpellier University Hospitals, Arnaud de Villeneuve Hospital, Montpellier, France, ³Klinik für Innere Medizin, Rheumatologie, Pneumologie, Nephrologie und Diabetologie, Medius Kliniken, Akademisches Lehrkrankenhaus der Universität Tübingen, Kirchheim unter Teck, Germany, ⁴Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, Canada, ⁵Guy’s Severe Asthma Centre, Guy's and St Thomas’ NHS Trust, London, and School of Immunology and Microbial Sciences, King's College London, London, United Kingdom, ⁶University of Cambridge, Cambridge, United Kingdom, ⁷Department of Medicine, McMaster University and St. Joseph’s Healthcare, Hamilton, ON, Canada, ⁸Mayo Clinic, Rochester, MN, ⁹Cochin Hospital, Paris, France, ¹⁰Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca,, Gothenburg, Sweden, ¹¹BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ¹²Respiratory & Immunology, AstraZeneca, Bengaluru, Karnataka, India, ¹³Late-stage Respiratory & Immunology, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden, ¹⁴Late-Stage Respiratory and Immunology, BioPharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom, ¹⁵Department of Medicine, National Jewish Health, Denver, ¹⁶University of Pennsylvania, Philadelphia, PA
Background/Purpose: Results from the ongoing open-label extension (OLE) of the MANDARA trial (NCT04157348) have demonstrated the efficacy of two years of anti-interleukin-5/receptor (anti-IL-5/R) therapies in…
Abstract Number: 1889 • ACR Convergence 2025
Navigating Diagnostic Challenges: Insights into the Patient Journey and Delays in Diagnosing Dermatomyositis from a Real-world Survey in the United States and Europe
Esther Yi¹, Jason Xenakis¹, Chris Blazos², Jade Garratt-Wheeldon², James Piercy², Peter Anderson² and Rohit Aggarwal³, ¹Pfizer Inc., New York, United States of America, New York, ²Adelphi Real World, Bollington, United Kingdom, Bollington, United Kingdom, ³University of Pittsburgh, Rheumatology and Clinical Immunology, Pittsburgh, United States of America, Pittsburgh, PA
Background/Purpose: Idiopathic inflammatory myopathies (IIMs) are a heterogenous group of rare autoimmune inflammatory rheumatic diseases, including dermatomyositis (DM).Methods: Data were drawn from the Adelphi Real…
Abstract Number: 1890 • ACR Convergence 2025
Quantifying the Inflammatory Toll: Smoking-Attributable Rheumatoid Arthritis Burden Across the Globe, 1990–2021
Eva Kalra¹, Shreyaa Rajpal², Twisha Parikh³, Drumadala Gajbhiye⁴, Chethan Raj Gundoji⁵, Sagar Patel⁶, Jay Patel⁷, Neelima Sinha⁸, Nikhil Rayarakula⁹, Dhwani Vaghani¹⁰ and Hardik Dineshbhai Desai¹¹, ¹Trident Medical Center, North Charleston, SC, ²Osmania Medical College, Hyderabad, Telangana, India-⁵⁰⁰⁰⁹⁵, Hyderabad, India, ³GMERS Medical College and Hospital, Gotri, Vadodara, India ³⁹⁰⁰²¹, Vadodara, India, ⁴Government medical college Akola Maharashtra India ⁴⁴⁴⁰⁰¹, Akola, India, ⁵Internal Medicine, Government Medical College Nizamabad, Nizamabad, Telangana, India, ⁵⁰³⁰⁰¹, Nizamabad, India, ⁶Internal medicine -Ward Wizard Medicare Pvt Ltd, Nadiad, Gujarat, India, ³⁸⁷⁰⁰², Nadiad, India, ⁷MGM Medical College, Aurangabad, Maharashtra, India-⁴³¹⁰⁰³, Aurangabad, India, ⁸Department of Medicine, Kurji Holy Family Hospital, Patna, Bihar, India, ⁸⁰⁰⁰¹⁰, Patna, India, ⁹College of Public Health, Kent State University, Kent,Ohio, USA, ⁴⁴²⁴²., Kent, OH, ¹⁰Internal Medicine, MGM Medical College, Aurangabad, Maharashtra, India,⁴³¹⁰⁰³, Aurangabad, India, ¹¹Ahmedabad, Gujarat, India, ³⁸²³⁵⁰, Ahmedabad, India
Background/Purpose: Rheumatoid arthritis (RA), a chronic systemic inflammatory disorder, imposes a significant global health burden. Smoking is a well-established modifiable risk factor implicated in both…
Abstract Number: 1799 • ACR Convergence 2025
Validating the Gouty Arthritis Alleviating Effects of Cerevisterol through Integrated In Silico, In Vitro, and In Vivo Studies
Xiao-Na Ma¹, Mei-Feng Shi¹, Qian Chen¹, Fang-Shu Zou¹, Wei Feng¹, Qing-Ping Liu¹, Chang-Song Lin¹, Nan Li², Xiao-Bao Liu¹ and Qiang Xu¹, ¹Guangzhou University of Traditional Chinese Medicine, Guangzhou, China (People's Republic), ²School of Traditional Chinese Medicine, Jinan University, Guangzhou, China (People's Republic)
Background/Purpose: Zhuling has traditionally been utilized in the treatment of gouty arthritis (GA). Although its therapeutic benefits are recognized, the molecular mechanisms underlying Zhuling's action…
Abstract Number: 1870 • ACR Convergence 2025
Paracrine WNT Signaling Modulates Profibrotic Macrophage Metabolic Activation in Systemic Sclerosis
emily Morris¹, Helen Jarnagin¹, Chen-Yu Wang¹, Michael Whitfield² and Patricia Pioli³, ¹Dartmouth College, Lebanon, NH, ²Geisel School of Medicine, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Lebanon, NH
Background/Purpose: An immune fibrotic axis consisting of activated macrophages (MØs) and fibroblasts has been identified in autoimmune systemic sclerosis (SSc) that drives disease across affected…
Abstract Number: 1885 • ACR Convergence 2025
Sex-specific Associations of Anthropometrics, Smoking and Eduction with the Risk of Rheumatoid Athritis: A Nested Case-Control Study
Carl Turesson¹, Linnea arvidsson², Emil Rydell¹ and Ulf Bergström³, ¹Lund University, Malmö, Sweden, ²Lund University, Malmö, ³Lund University, Malmö, Sweden
Background/Purpose: Smoking is an established risk factor for rheumatoid arthritis (RA), and there is also evidence for an association with socioeconomic factors. As RA is…
Abstract Number: 1786 • ACR Convergence 2025
SEV-101, A Regenerative Exosome Therapeutic for the Treatment of Osteoarthritis
Beth Lindborg¹, Amanda Vegoe², Michael Williams¹, Parthasarathy Rangarajan³, Marc Tompkins⁴, Sabarinathan Ramachandran⁵ and Timothy O'Brien⁶, ¹Sarcio, Inc., St. Paul, ²Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, St. Paul, ³Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, ⁴Department of Orthopedic Surgery, University of Minnesota, Sarcio, Inc., Minneapolis, ⁵Schulze Diabetes Institute, Department of Surgery, University of Minnesota, Minneapolis, MN, ⁶Department of Veterinary Population Medicine and Stem Cell Institute, University of Minnesota, Sarcio, Inc, Minneapolis
Background/Purpose: Osteoarthritis (OA) is a chronic, debilitating joint disease affecting 595 million people worldwide, including over 32 million in the United States. It is characterized…
Abstract Number: 1898 • ACR Convergence 2025
Assessing Representation in a Nation-Wide Psoriasis Registry: A Single-Institution Comparison
Evelyn Fagan¹, Joseph McGrath¹, Calla Sullivan¹, Mackenzie Kilton¹, Kaeli Samson², Kaleb Michaud³ and Sarah Lonowski¹, ¹University of Nebraska Medical Center Department of Dermatology, Omaha, NE, ²University of Nebraska Medical Center Department of Biostatistics, Omaha, NE, ³University of Nebraska Medical Center, Omaha, NE
Background/Purpose: Ensuring that data registries include a representative sample is crucial for obtaining findings that can be generalized to the larger population. This comparative observational…
Abstract Number: 1899 • ACR Convergence 2025
Regional Variability in SLE Damage Accumulation by Disease Activity Across the Lupus Federated Data Network (LupusNet)
Manuel Ugarte-Gil¹, Sarah Gasman², Federico Zazzetti³, Ashley Orillion², Anna Sheahan⁴, Clair Blacketer², Michel van Speybroeck⁵, Reyhan Sonmez⁶, Erika Noss², Rocío Gamboa-Cárdenas⁷, Víctor Pimentel-Quiroz⁸, Kaleb Michaud⁹, Patti Katz¹⁰, Rangi Kandane-Rathnayake¹¹, Eric Morand¹², Worawit Louthrenoo¹³, Alberta Hoi¹⁴, Yi-Hsing Chen¹⁵, Jiacai Cho¹⁶, Laniyati Hamijoyo¹⁷, Shue Fen Luo¹⁸, Sandra Navarra¹⁹, Mandana Nikpour²⁰, José María Pego-Reigosa²¹, Iñigo Rúa-Figueroa²², Zulema Plaza²³, Maria Galindo-Izquierdo²⁴, Julia Martínez Barrio²⁵, Jaime Calvo²⁶, Antonio Fernández-Nebro²⁷, Raúl Menor Almagro²⁸, EVA GLORIA TOMERO MURIEL²⁹, Javier Narváez³⁰ and Chetan S. Karyekar³¹, ¹Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Peru; Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Peru, Lima, Peru, ²Johnson & Johnson, Spring House, PA, USA, Spring House, PA, ³Johnson & Johnson, Horsham, PA, USA, Ambler, PA, ⁴Johnson & Johnson, Horsham, PA, USA, Horhsam, PA, ⁵Johnson & Johnson, Beerse, Belgium, Beerse, Belgium, ⁶Capgemini Consulting, Zurich, Switzerland, Zurich, Switzerland, ⁷Universidad Científica del Sur, Lima, Peru, ⁸Grupo Peruano de Estudio de Enfermedades Autoinmunes Sistémicas, Universidad Científica del Sur, Lima, Perú; Rheumatology Department, Hospital Guillermo Almenara Irigoyen, EsSalud, Lima, Perú, Lima, Peru, ⁹University of Nebraska Medical Center, Omaha, NE, ¹⁰UCSF, San Rafael, CA, ¹¹Center for Inflammatory Diseases, Monash University, Clayton, Victoria, Australia, ¹²Centre for Inflammatory Diseases, Monash University and Monash Health, Melbourne, Victoria, Australia, ¹³Chiang Mai University Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Chiang Mai, Thailand, Chiang Mai, Thailand, ¹⁴Centre for Inflammatory Diseases, Monash University and Department of Rheumatology, Monash Health, Clayton, Victoria, Australia, ¹⁵Taichung Veterans General Hospital, Division of Allergy, Immunology and Rheumatology, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ¹⁶National University Hospital, Rheumatology Division, Department of Medicine, Singapore, Singapore, Singapore, Singapore, ¹⁷Padjadjaran University/Hasan Sadikin General Hospital, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Bandung, Indonesia, Badung, Indonesia, ¹⁸Chang Gung Memorial Hospital, Chang Gung University, Department of Rheumatology, Allergy and Immunology, Taipei, Taiwan, Taoyuan, Taiwan (Republic of China), ¹⁹University of Santo Tomas, Manila, Philippines, ²⁰University of Sydney, School of Public Health, Faculty of Medicine and Health, Sydney, New South Wales, Australia; St Vincent’s Hospital Melbourne, Department of Rheumatology, Fitzroy, Victoria, Australia, Melbourne, Victoria, Australia, ²¹Department of Rheumatology, University Hospital of Vigo, Vigo, Spain; IRIDIS Group (Investigation in Rheumatology and Immune-Diseases), Galicia Sur Health Research Institute, Vigo, Spain, ²²Hospital de Gran Canaria Doctor Negrin, Las Palmas GC, Spain, ²³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, Madrid, Spain, ²⁴Department of Rheumatology, Hospital Universitario ¹² de Octubre, Madrid, Spain, Madrid, Spain, ²⁵Department of Rheumatology, Hospital Gregorio Marañón, Madrid, Spain, Madrid, Madrid, Spain, ²⁶Department of Rheumatology, Hospital Universitario Araba, School of Medicne, Universidad del País Vasco, BIOARABA Health Research Institute, Vitoria, Spain, Vitoria, Pais Vasco, Spain, ²⁷Hospital Regional Universitario de Malaga, Malaga, Spain, Malaga, Spain, ²⁸Department of Rheumatology, Hospital de Jerez, Spain, Puerto De Santa María, Spain, ²⁹Hospital Universitario de la Princesa, Madrid, Spain, ³⁰Hospital Universitario de Bellvitge, Barcelona, Spain, ³¹Johnson & Johnson, Spring House, PA, USA, Spring House
Background/Purpose: SLE is characterized by heterogeneous clinical presentation and periods of flare and remission, with variation in management globally. A goal for SLE management is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].